durvalumab|abdominal pain
durvalumab|abdominal pain lower
durvalumab|abdominal pain upper
durvalumab|abortion
durvalumab|acute kidney injury
durvalumab|adrenal insufficiency
durvalumab|anemia
durvalumab|aseptic meningitis
durvalumab|asthenia
durvalumab|candiduria
durvalumab|cardiorespiratory arrest
durvalumab|colitis
durvalumab|constipation
durvalumab|cystitis
durvalumab|death
durvalumab|decreased appetite
durvalumab|dehydration
durvalumab|dermatitis
durvalumab|dermatitis acneiform
durvalumab|dermatitis psoriasiform
durvalumab|diabetes insipidus
durvalumab|diarrhea
durvalumab|discomfort
durvalumab|eczema
durvalumab|edema peripheral
durvalumab|embryo-fetal toxicity
durvalumab|endocrinopathies
durvalumab|erythema multiforme
durvalumab|exertional dyspnea
durvalumab|fatal
durvalumab|fatigue
durvalumab|fetal loss
durvalumab|flank pain
durvalumab|general physical health deterioration
durvalumab|hemolytic anemia
durvalumab|hepatitis
durvalumab|hyperbilirubinemia
durvalumab|hypercalcemia
durvalumab|hyperglycemia
durvalumab|hyperkalemia
durvalumab|hypermagnesemia
durvalumab|hyperthyroidism
durvalumab|hypoalbuminemia
durvalumab|hypokalemia
durvalumab|hyponatremia
durvalumab|hypophagia
durvalumab|hypophysitis
durvalumab|hypopituitarism
durvalumab|hypothyroidism
durvalumab|ileus
durvalumab|immune thrombocytopenic purpura
durvalumab|increase in neonatal deaths
durvalumab|increased alkaline phosphatase
durvalumab|increased alt
durvalumab|increased ast
durvalumab|increased creatinine
durvalumab|infection
durvalumab|infusion reaction
durvalumab|infusion related reaction
durvalumab|infusion-related reactions
durvalumab|interstitial lung disease
durvalumab|keratitis
durvalumab|lethargy
durvalumab|lichen planus
durvalumab|liver injury
durvalumab|localized edema
durvalumab|lymphedema
durvalumab|lymphopenia
durvalumab|malaise
durvalumab|musculoskeletal chest pain
durvalumab|musculoskeletal pain
durvalumab|myalgia
durvalumab|myocardial infarction
durvalumab|myocarditis
durvalumab|myositis
durvalumab|nausea
durvalumab|neck pain
durvalumab|necrotizing fasciitis
durvalumab|nephritis
durvalumab|neutropenia
durvalumab|ocular inflammatory toxicity
durvalumab|osteomyelitis
durvalumab|peripheral edema
durvalumab|peripheral swelling
durvalumab|pneumonitis
durvalumab|premature delivery
durvalumab|premature neonatal death
durvalumab|productive cough
durvalumab|psoriasis
durvalumab|pyrexia
durvalumab|rash
durvalumab|rash erythematous
durvalumab|rash maculo-papular
durvalumab|rash papular
durvalumab|rash pruritic
durvalumab|rash pustular
durvalumab|scrotal edema
durvalumab|scrotal swelling
durvalumab|sepsis
durvalumab|skin toxicity
durvalumab|stillbirth
durvalumab|thyroiditis
durvalumab|tumor associated fever
durvalumab|type 1 diabetes mellitus
durvalumab|urinary tract infection
durvalumab|urosepsis
durvalumab|urticaria
durvalumab|uveitis
durvalumab|vitiligo